On October 13, 2026 Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, reported that Jose Conejo-Garcia, MD, PhD, inventor of Anixa’s CAR-T therapy for ovarian cancer, will deliver a keynote presentation at the 2026 Ovarian Cancer Midwest Focus Conference. The conference, hosted by Mayo Clinic and University of Minnesota, will be held November 2–3, 2026, in Rochester, Minnesota.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Dr. Conejo-Garcia’s presentation is titled "Closing in: Cracking Ovarian Cancer’s Resistance to Immunotherapy." He is Professor of Immunology in the Department of Integrative Immunobiology at the Duke University School of Medicine.
"Dr. Conejo-Garcia’s research into the immune biology of ovarian cancer led to the invention of the technology underlying lira-cel, our ovarian cancer CAR-T therapy," said Dr. Amit Kumar, Chairman and CEO of Anixa. "We are pleased that he will share his insights with the ovarian cancer research community at this conference."
Anixa’s ovarian cancer CAR-T therapy, liraltagene autoleucel, or lira-cel, is being evaluated in an ongoing Phase 1 clinical trial in collaboration with Moffitt Cancer Center. The investigational therapy uses chimeric endocrine receptor-T cell technology designed to target the follicle-stimulating hormone receptor, which is expressed on ovarian cancer cells but has limited expression in healthy tissues. The trial is designed to assess safety, tolerability, and preliminary signs of efficacy across escalating dose levels. To date, no dose-limiting toxicities have been observed, and four patients have surpassed one year of survival following treatment, with one of them having survived beyond two years. In addition, the first patient treated at the highest dose to date exhibited stable disease 90 days after treatment.
Presentation details:
Event: 2026 Ovarian Cancer Midwest Focus Conference
Speaker: Jose Conejo-Garcia, MD, PhD
Topic: Closing in: Cracking Ovarian Cancer’s Resistance to Immunotherapy
Location: Marriott Hotel, Rochester, Minnesota
Presentation date and time: 9:00 AM CT, Tuesday, November 3, 2026
The Ovarian Cancer Midwest Focus Conference brings together researchers, clinicians, patient advocates and others affected by ovarian cancer to share advances in research and care. Established at the University of Minnesota, the conference highlights work at Midwestern institutions and beyond, with a program spanning basic science, clinical research, emerging treatments and patient perspectives.
(Press release, Anixa Biosciences, OCT 13, 2026, View Source [SID1234673365])